EMA Authorised: Afstyla (lonoctocog alfa) — CSL Behring GmbH

View source ↗

Summary

Afstyla (lonoctocog alfa) by CSL Behring GmbH has been authorised in the EU for the treatment of Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Afstyla (eftrenonacog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: CSL Behring GmbH. Decision date: 17/12/2024